These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
634 related articles for article (PubMed ID: 28445298)
21. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization. Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317 [TBL] [Abstract][Full Text] [Related]
22. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102 [TBL] [Abstract][Full Text] [Related]
23. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Kudo M; Arizumi T; Ueshima K; Sakurai T; Kitano M; Nishida N Dig Dis; 2015 Oct; 33(6):751-8. PubMed ID: 26488473 [TBL] [Abstract][Full Text] [Related]
24. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F; Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853 [TBL] [Abstract][Full Text] [Related]
25. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
26. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study. Adhoute X; Pénaranda G; Raoul JL; Blanc JF; Edeline J; Conroy G; Perrier H; Pol B; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Bronowicki JP; Bourlière M Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):433-40. PubMed ID: 26695429 [TBL] [Abstract][Full Text] [Related]
27. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366 [TBL] [Abstract][Full Text] [Related]
28. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. Li J; Hou Y; Cai XB; Liu B World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447 [TBL] [Abstract][Full Text] [Related]
29. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model. Chan YC; Kabiling CS; Pillai VG; Aguilar G; Wang CC; Chen CL World J Surg; 2015 Jun; 39(6):1510-8. PubMed ID: 25665673 [TBL] [Abstract][Full Text] [Related]
30. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206 [TBL] [Abstract][Full Text] [Related]
31. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160 [TBL] [Abstract][Full Text] [Related]
32. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F; Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596 [TBL] [Abstract][Full Text] [Related]
33. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. Nakazawa T; Hidaka H; Shibuya A; Okuwaki Y; Tanaka Y; Takada J; Minamino T; Watanabe M; Kokubu S; Koizumi W BMC Gastroenterol; 2014 May; 14():84. PubMed ID: 24886354 [TBL] [Abstract][Full Text] [Related]
34. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. Ha Y; Shim JH; Kim SO; Kim KM; Lim YS; Lee HC J Gastroenterol Hepatol; 2014 Apr; 29(4):787-93. PubMed ID: 24224567 [TBL] [Abstract][Full Text] [Related]
35. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK; BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083 [TBL] [Abstract][Full Text] [Related]
36. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Kimura H; Ohkawa K; Miyazaki M; Sakakibara M; Imanaka K; Tamura T; Sueyoshi H; Takada R; Fukutake N; Uehara H; Ashida R; Ioka T; Nakazawa T; Nakanishi K; Katayama K Hepatol Int; 2017 Jan; 11(1):105-114. PubMed ID: 27766479 [TBL] [Abstract][Full Text] [Related]
37. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662 [TBL] [Abstract][Full Text] [Related]
38. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250 [TBL] [Abstract][Full Text] [Related]
39. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992 [TBL] [Abstract][Full Text] [Related]
40. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]